Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07033026 · ClinicalTrials.gov registry record · Phase 2

An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.

A Phase 2 study of Colorectal Cancer and CRC, Colorectal Cancer, sponsored by NGM Biopharmaceuticals.

Recruiting
Registry status
Phase 2
Development phase
136
Enrollment target
1
Study location

NCT07033026: Recruiting Phase 2 study of Colorectal Cancer and CRC, Colorectal Cancer, sponsored by NGM Biopharmaceuticals.

NCT07033026 is a Phase 2 study of Colorectal Cancer and CRC, Colorectal Cancer that is actively recruiting participants, run by NGM Biopharmaceuticals. The registered enrollment target is 136 participants, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07033026, a Phase 2 study of Colorectal Cancer and CRC, Colorectal Cancer, is actively recruiting participants, sponsored by NGM Biopharmaceuticals.

RECRUITING
Registry status
Phase 2
Development phase
136 participants
Enrollment target
1
Study location

Study Summary

A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

Primary Outcome

To evaluate the effect of NGM120 compared to placebo on body weight.

Conditions Studied

Colorectal Cancer CRC, Colorectal Cancer Cancer Cachexia

Interventions

  • DRUG NGM120 Q4W
  • DRUG NGM120 Q8W
  • DRUG Placebo given

Study Locations (1)

Texas

  • NGM Clinical Study Site - Laredo

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2025-06
Est. Completion 2027-12
Phase Phase 2
NGM Biopharmaceuticals

18 total trials

What NCT07033026 shows while recruiting

NCT07033026 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, below the 1,544-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (91% lower).

The record links to 3 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which NGM120 Q4W is the first listed.

NCT07033026 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT07033026 about?

NCT07033026 is a clinical study titled "An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.". A multi-center evaluation of NGM120 in a randomized, double-blind, placebo-controlled study in participants with colorectal cancer who have cancer cachexia.

What is the current status of trial NCT07033026?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2025-06. Estimated completion is 2027-12.

What conditions does trial NCT07033026 study?

This clinical trial studies the following conditions: Colorectal Cancer, CRC, Colorectal Cancer, Cancer Cachexia.

What interventions are being tested in trial NCT07033026?

The interventions under investigation include: NGM120 Q4W (DRUG), NGM120 Q8W (DRUG), Placebo given (DRUG).

Who is sponsoring clinical trial NCT07033026?

This trial is sponsored by NGM Biopharmaceuticals, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07033026 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT07033026's enrollment target sits among peer trials

136 183rd of 381 higher than 198 of 381 other Colorectal Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01555892 · 136 participants · Phase 1

    Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

  • NCT03216525 · 136 participants · Phase 3

    Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

  • NCT04476901 · 136 participants · Phase 2

    Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

  • NCT04603898 · 136 participants · NA

    Oxalate Formation From Ascorbic Acid

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

More recruiting context for NCT07033026

Source: ClinicalTrials.gov NCT07033026, the US trial registry maintained by the National Library of Medicine. NCT07033026 (mid enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.